Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/2/2011

CUPERTINO, Calif., March 2, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2010. Total revenues were $8.5 million for the three months ended December 31, 2010, up from $4.9 million for the three months ended December 31, 2009.  Net loss for the three months ended December 31, 2010 was $5.3 million, down from a net loss of $8.6 million for the same period in 2009.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

For the fiscal year ended December 31, 2010, total revenues were $31.6 million, up from $24.5 million for the same period in 2009.  Net loss for the year ended December 31, 2010 was $22.9 million, down from a net loss of $30.3 million for the same period in 2009.

At December 31, 2010, we had cash and investments of $49.6 million, compared to cash and investments of $41.6 million at December 31, 2009.  We have no debt obligations, other than normal liabilities associated with running our business.

"2010 was a strong year for DURECT in product development and business development, with the establishment of a major collaboration around POSIDUR™ that enabled us to generate positive cash flow for the year," stated James E. Brown, D.V.M., President and CEO of DURECT.  "We look forward to the potential approval of REMOXY® in 2011 and subsequent launch by Pfizer."

Key milestones met in 2010 include:

  • Resubmission of the REMOXY NDA by King Pharmaceuticals, with an anticipated PDUFA goal date of June 23, 2011
  • Initiation of and continued enrollment in the POSIDUR U.S. pivotal Phase III trial
  • Establishment of Hospira as POSIDUR's development and commercialization partner for the U.S. and Canada
  • Commencement of a Phase IIb s
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
    2. DURECT Corporation Announces Third Quarter 2008 Financial Results
    3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
    4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    5. Pharmos Corporation Reports 2008 Second Quarter Results
    6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
    7. Genaera Corporation Announces Second Quarter Financial Results
    8. MannKind Corporation Reports Second Quarter Financial Results
    9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
    10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
    11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/26/2015)... May 26, 2015   PDI , a ... announced that Oakwood Healthcare in Dearborn, ... winning entry in Delivering the Difference ... display excellence in building collaborative relationships between infection ... healthcare facilities.  Oakwood Healthcare,s infection ...
    (Date:5/26/2015)... May 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced ... convened at Shutters on the Beach in ... status of the Company,s innovative Metronomic Biofeedback Pump (MBP), ... deliver chemotherapy over time to a target site of ... and biofeedback system in real-time.  ...
    (Date:5/26/2015)... LOS ANGELES , 26. mája 2015 /PRNewswire/ ... ďakuje v mene svojej rodiny prezidentom Barackovi Obamovi ... vyjadrenú v súvislosti so stratou Dr. Rongxiang ... - http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu ... svojej dobe a jeho odhodlanie v oblasti vedy ...
    (Date:5/26/2015)... May 26, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that all outstanding common ... exercised prior to their expiry on June 15, 2015, ... million. "We thank our shareholders for their ... CEO of Asterias. "This exercise of warrants represents a ...
    Breaking Biology Technology:PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, O legende 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3
    ... March 20, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Inc. has received approval from the United States Food ... (ANDA) for Ibandronate 150mg tablets, the generic equivalent to ... product in the second quarter. BONIVA® 150mg tablets had ...
    ... 20, 2012 /PRNewswire-iReach/ -- FirstMark today ... for the multiple biomarker cardiovascular blood test PREvent. ... announcing the completion of the clinical study demonstrating ... risk of near-term (2-3 years) myocardial infarction, and ...
    ... MURRAY, Utah, March 20, 2012 Creative Bioscience, a leading ... hCG1234™ , African Mango Lean ™, African ... Diet 1234 ™ and its new Raspberry Ketone ... all Sprouts Farmers Markets locations across the West ...
    Cached Biology Technology:Watson's Generic BONIVA® 150mg Receives FDA Approval 2Expanded Findings for FirstMark's Completed Clinical Study for Predicting Near-Term (2-3 Years) MI 2Expanded Findings for FirstMark's Completed Clinical Study for Predicting Near-Term (2-3 Years) MI 3Creative Bioscience All-Natural Dietary Supplements Now Available at Sprouts Farmers Market 2Creative Bioscience All-Natural Dietary Supplements Now Available at Sprouts Farmers Market 3
    (Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
    (Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
    (Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
    Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
    ... the battle of the sexes, African electric fish couples ... also engage in a sort of dueling "electric duet." ... and behavioral displays in breeding and nonbreeding Brienomyrus brachyistius, ... electric fields from a batterylike organ in their tails ...
    ... brain consists of billions of nerve cells enabling to ... experience, touch, smell or fear, millions of neurons in ... each other by chemical and electrical impulses to compute ... regions. With 20,000 - 25,000 genes in our genome, ...
    ... Board: NRGX) today announced the publication in the June 23 ... the first ever gene therapy trial for Parkinson’s disease and ... own brain cells for any adult neurodegenerative disease. , ... with advanced Parkinson’s disease demonstrated both a lack of adverse ...
    Cached Biology News:Turn-ons and turn-offs for neurons 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4
    AC input: 50-60 Hz230 V...
    ... Microarray Slide features an ultra-thin nitrocellulose ... is the first protein microarray slide ... nitrocellulose in a thin film with ... ,The PATH™ Slide can be ...
    AC input: 50-60 Hz 115-120 V...
    ... hybridization of DNA or Protein microarrays printed ... glass slides. The proprietary design of the ... flatness, as is often the case with ... (67uL analytical cavity volume) eliminates the need ...
    Biology Products: